FDA Approves First Drug for Treatment of Chorea in Huntington's Disease
15.08.08 - 22:41 ... source : FDA
... The U.S. Food and Drug Administration has approved Xenazine (tetrabenazine) for the treatment of chorea in people with Huntington's disease. Chorea is the jerky, involuntary movement that occurs in people with this disease. Xenazine is a new drug and is the first treatment of any kind approved in the United States for any symptom of Huntington's disease. Currently there are no other drugs that are FDA-approved to treat chorea. Serious side effects reported with use of Xenazine include depression and suicidal thoughts and actions. Xenazine should not be used in patients who are actively suicidal or in patients with untreated depression. Concerns about the risk of suicide are heightened in all patients with Huntington's disease. "Xenazine represents hope for patients and families dealing with this difficult disease," said Timothy Coté, M.D., M.P.H., director of FDA's Office of Orphan Pr ...» Next (HTML)
Similar news
100% | 29.07.08 - 22:22 ... source : FDA
... generic versions of Depakote delayed-release tablets (divalproex sodium). Depakote is approved by the FDA for the treatment of seizures, bipolar disorder and migraine headaches. "Generic drugs undergo a rigorous scientific review to ensure that they will provide the patient with ...
99% | 09.07.08 - 14:22 ... source : Novo Nordisk - US
... Nordisk Inc. and Sciele Pharma, Inc. (NASDAQ: SCRX), today announced that the U.S. Food and Drug Administration (FDA) approved PrandiMet™ (repaglinide and metformin HCl) tablets, the first and only fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin®) ...
97% | 04.08.08 - 12:38 ... source : Novartis
... patients on combination therapies[1] Up to 80% of patients may need multiple medications to help them reach blood pressure goals[2] Single-pill combinations offer effective, convenient medications which could help patients reach treatment goals faster[3] High blood pressure is one of ...
96% | 23.07.08 - 16:50 ... source : AstraZeneca
... a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on June 30th and validation of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for ONGLYZA™ (saxagliptin). Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, ...
95% | 11.07.08 - 18:03 ... source : FDA
... is revising the way it communicates to drug companies when a marketing application cannot be approved as submitted. Under new regulations that govern the drug approval process, FDA's Center for Drug Evaluation and Research (CDER) will no longer issue "approvable" ...
